ERBB2 and breast carcinoma: The present study found that serum HER2 ECD level was correlated with a poor prognosis in primary breast cancer, and that patients with an elevated HER2 ECD level (>15.2 ng/ml) had a worse DMFS and BCSS than those with normal HER2 ECD levels.